Main finding: Few sight-threatening serious ocular adverse events occurred following Micro-Stent implantation, and clinical evidence of corneal decompensation was minimal
Purpose: To evaluate the safety and efficacy of insertion of the CyPass microstent in patients with mild-moderate POAG undergoing cataract surgery.
Study type: Safety extension of Randomized controlled trial
A higher proportion of subjects in the Micro-Stent group was able to achieve a reduction of ≥20% in intraocular pressure without using hypotensive medication than in the control group (46% VS 32.1%)
Changes in mean BCVA from baseline, clinical examinations, pachymetry, and VF mean deviation were similar in the 2 groups.
December 1, 2019
Clinical trial
Corneal Endothelial Cell Loss and Morphometric Changes 5 Years after Phacoemulsification with or without CyPass Micro-Stent.
Lass JH, Benetz BA, He J, Hamilton C, Von Tress M, Dickerson J, Lane S.
Main finding: In eyes with Open Angle Glaucoma, endothelial cell loss (ECL) after phacoemulsification is acute and stabilizes after 3 months, whereas ECL after phacoemulsification plus Micro-Stent implantation proceeds for at least 5 years.
Purpose: To evaluate long-term changes in corneal endothelial cells after phacoemulsification with or without supraciliary Micro-Stent in eyes with open-angle glaucoma and visually significant cataract.
Study type: Safety extension of Randomized controlled trial
Main finding: There was early and sustained IOP reduction and glaucoma medication use after insertion of the CyPass microstent in patients with mild-to-moderate POAG.
Purpose: To evaluate the safety and efficacy of insertion of the CyPass microstent in patients with mild-moderate POAG undergoing cataract surgery.
Source Archive